Biocryst Pharmaceuticals (BCRX) Inventory Average (2011 - 2026)

Biocryst Pharmaceuticals' Inventory Average history runs 13 years deep, the most recent figure standing at $5.7 million for Q1 2026.

• Quarterly Inventory Average fell 23.91% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (down 23.91% YoY) and the FY2025 annual result came in at $6.7 million, down 63.33% from the prior year.
• Inventory Average was $5.7 million for Q1 2026 at Biocryst Pharmaceuticals, up from $5.3 million in the prior quarter.
• Across five years, Inventory Average topped out at $29.2 million in Q1 2024 and bottomed at $5.1 million in Q3 2025.
• A 5-year average of $17.1 million and a median of $17.1 million in 2024 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2022 — Inventory Average jumped 156.63% — and 2024, when it slumped 78.8%.
• Biocryst Pharmaceuticals' Inventory Average stood at $27.3 million in 2022, then increased by 6.89% to $29.2 million in 2023, then tumbled by 73.16% to $7.8 million in 2024, then plunged by 32.07% to $5.3 million in 2025, then increased by 7.08% to $5.7 million in 2026.
• Business Quant data shows BCRX's Inventory Average at $5.7 million in Q1 2026, $5.3 million in Q4 2025, and $5.1 million in Q3 2025.